Use of R-mini-CHP in combination with polatuzumab vedotin (pola-R-mini-CHP) as the primary treatment in ≥80-year-old cases with diffuse large B-cell lymphoma

J Clin Exp Hematop. 2023;63(4):262-265. doi: 10.3960/jslrt.23043.

Authors

Affiliations

¹ Department of Hematology, Saitama Cancer Center, Saitama, Japan.
² Department of Clinical Laboratory Medicine, Saitama Cancer Center, Saitama, Japan.
³ Department of Inspection Engineering, Saitama Cancer Center, Saitama, Japan.
⁴ Department of Pathology, Saitama Cancer Center, Saitama, Japan.
⁵ Department of Hematology, Juntendo University Urayasu Hospital, Chiba, Japan.

No abstract available

Keywords: 80 years over; POLARIX; Pola-R-mini-CHP; R-mini-CHOP; diffuse large B-cell lymphoma.

MeSH terms

Aged, 80 and over
Antibodies, Monoclonal / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Humans
Immunoconjugates* / therapeutic use
Lymphoma, Large B-Cell, Diffuse* / drug therapy
Rituximab / therapeutic use

Substances

polatuzumab vedotin
Antibodies, Monoclonal
Immunoconjugates
Rituximab